People · Operator
Named in public records as an officer, director or promoter · active 2009–2022 · Biotechnology, Pharmaceuticals, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| X4 Pharmaceuticals, Inc | — | Biotechnology | Series C | $320.3M | $495.3M | 2016 |
| Lyra Therapeutics, Inc. | — | Biotechnology | Series D+ | $236.6M | $791.1M | 2009 |
| Faraday Pharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $115.5M | $830.5M | 2022 |
| Icelandic Provisions, Inc. | — | Other | Series B | $79.2M | $32.4M | 2015 |
| Pulmatrix Inc | — | Biotechnology | Series B | $69.6M | $396.9M | 2015 |
| Pulmatrix, Inc. | — | Pharmaceuticals | Series B | $62.9M | $86.2M | 2015 |
| Ankyra Therapeutics, Inc. | — | Biotechnology | Series C | $59.5M | $1.2B | 2020 |
| MicroCHIPS, Inc. | — | Biotechnology | Series B | $27.9M | $740.1M | 2009 |
| Seer Biosciences, Inc. | — | Biotechnology | Series A | $6.0M | $216.9M | 2017 |
Terrance McGuire at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Terrance McGuire on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Langer | 3 | 36 |
| Steven Gillis | 3 | 23 |
| Michael Higgins | 2 | 9 |
| SCOTT ROCKLAGE | 2 | 9 |
| Robert Clarke | 2 | 7 |
| Tillman Gerngross | 2 | 5 |
| Kurt Graves | 2 | 5 |
| David Hava | 2 | 2 |
| David Maki | 2 | 2 |
| Carl Gordon | 1 | 24 |
| Robert Nelsen | 1 | 22 |
| Michael Ross | 1 | 18 |
| Carmichael Roberts | 1 | 15 |
| Michael Greeley | 1 | 15 |
| Robert S Langer | 1 | 14 |
| Ajay Royan | 1 | 13 |
| Amy Schulman | 1 | 11 |
| Edward Anderson | 1 | 8 |
| CARL L. GORDON | 1 | 7 |
| Guido Neels | 1 | 7 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.